Financial News · Live Terminal

Page 1 of 296

Craig Hallum Upgrades Backblaze to Buy From Hold, $16 Price Target

Daiwa Downgrades JD.com to Hold From Buy, Adjusts Price Target to $27 From $47

JD.com (JD) has an average rating of overweight and mean price target of $39.89, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $26.32, Change: $-0.70, Percent Change: -2.61%

$JD

Research1h ago

Daiwa Downgrades PDD to Hold From Buy, Adjusts Price Target to $80 From $145

PDD (PDD) has an average rating of overweight and mean price target of $118.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $76.35, Change: $-1.77, Percent Change: -2.26%

$PDD

Research3h ago

Keyera Price Target Raised to $61 at ATB

ATB Capital Markets raised its price target on Keyera Corp. (KEY.TO) to $61 from $58.Analyst Nate Heywood maintained a Sector Perform rating on shares of the Calgary-based oil and gas company after it closed its $604 million equity offering and $1 billion note offering associated with its acquisition of the remaining 50% non-operating interest in the KAPS Pipeline."The funding plan near 50/50 equity to debt is not expected to impact KEY's target to return toward the 2.5x-3.0x net debt to EBITDA range by 2028," Heywood said in a note to clients."The acquisition provides greater flexibility and efficiency for customers enhances KEY's long-term cash flow quality with an average contract term of ~12 years and 75% under take-or-pay," the analyst said.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$KEY.TO

Research4h ago

Guggenheim Downgrades Apogee Therapeutics to Neutral From Buy

Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $130.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$APGE

Research4h ago

SNB Capital Cuts Advanced Petrochemical's PT, Keeps at Neutral

SNB Capital on Tuesday decreased the price target for propylene and polypropylene products company Advanced Petrochemical Co. (SASE:2330) to 27.10 Saudi riyals from 37.20 riyals and affirmed its neutral rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

SASE:2330

Research4h ago

HSBC Downgrades Hermès International to Hold, Reduces PT

HSBC on Tuesday lowered French luxury fashion group Hermès International (RMS.PA) to hold from buy and reduced its price target to 1,870 euros from 2,100 euros.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$RMS.PA

Research4h ago

Morgan Stanley Upgrades Demant to Overweight, Boosts PT

Morgan Stanley on Tuesday upgraded Danish hearing healthcare and audio technology group Demant (DEMANT.CO) to overweight from equal weight and raised its price target to 290.00 Danish kroner from 210.00 kroner.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DEMANT.CO

Research4h ago

EFG-Hermes Brokerage Downgrades Lumi Rental to Neutral, Cuts PT

EFG-Hermes Brokerage on Tuesday lowered car rental company Lumi Rental (SASE:4262) to neutral from buy and reduced its price target to 38 Saudi riyals from 77.50 riyals.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

SASE:4262

Research4h ago

Jyske Bank Begins AL Sydbank Coverage at Buy

Jyske Bank on Tuesday initiated its coverage of Danish lender AL Sydbank (ALSYDB.CO) with a buy rating and a price target of 750 Danish kroner.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$0MGE.L$ALSYDB.CO

Research4h ago

Autonomous Research Downgrades Legal & General Group to Underperform

Autonomous Research on Tuesday downgraded British insurer Legal & General Group (LGEN.L) to underperform from neutral, while maintaining the price target at 2.60 pounds sterling.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$LGEN.L

Research4h ago

UBS Upgrades Intermediate Capital Group to Buy Rating

UBS on Tuesday upgraded British alternative assets manager Intermediate Capital Group (ICG.L) to buy from neutral, while maintaining its price target at 21.50 pounds sterling.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ICG.L

Research4h ago

HSBC Downgrades Air Arabia to Reduce Rating, Boosts PT

HSBC on Tuesday downgraded Dubai-listed low-cost carrier Air Arabia (DFM:AIRARABIA) to reduce from hold, while increasing its price target to 5 Emirati dirhams from 4 dirhams.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

DFM:AIRARABIA

Research4h ago

Lake Street Initiates Coverage on Vivani Medical With Buy Rating, $4 Price Target

Vivani Medical (VANI) has an average rating of Buy and mean price target of $3.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$VANI

Research4h ago

Alimentation Couche-Tard Price Target Raised to $106 at RBC

RBC Capital Markets raised its price target on Alimentation Couche-Tard Inc. (ATD.TO) to $106 from $104.Analyst Irene Nattel maintained an Outperform rating on shares of the Canadian multinational convenience store operator following its quarterly results.The company ended fiscal 2026 with "strong and better than expected KPI's/ financials, notably sequential step-up in US SSS and higher Y/Y GP margins," Nattel said in a note to clients."We have been very clear in our view that the key to ATD multiple re-rating is delivering on the financial objectives outlined" at its February investor day, the analyst said.RBC reiterated a "constructive view on ATD and upside bias to valuation based on improving results, track record of disciplined capital allocation/ability to deliver across cycles."(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ATD.TO

Research5h ago

Deutsche Bank Downgrades Apogee Therapeutics to Hold From Buy, Adjusts Price Target to $135 From $116

$APGE

Research5h ago

Deutsche Bank Initiates Coverage on Insulet With Buy Rating, $190 Price Target

Insulet (PODD) has an average rating of Buy and mean price target of $238.79, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$PODD

Research5h ago

Deutsche Bank Initiates Coverage on Tandem Diabetes Care With Hold Rating, $15.50 Price Target

Tandem Diabetes Care (TNDM) has an average rating of overweight and mean price target of $29.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TNDM

Research5h ago

Primaris REIT Price Target Raised to $25 at CIBC

CIBC Capital Markets raised its price target on Primaris REIT (PMZ-UN.TO) to C$25 from C$22.Analyst Tal Woolley maintained an Outperformer rating on shares of the Canadian shopping center-focused real estate company."We believe the outlook for PMZ can continue to improve in a Canadian retail environment with a lack of traditional department store anchor tenants," Woolley said in a note to clients."We also expect PMZ to soon offer another positive leasing update on its 1.3 million square feet of vacant anchor space," the analyst said.CIBC's estimate of the company's return on invested capital average 7.4% over the next two years. That's "well ahead of the balance of our REIT coverage (averaging 5.8%), delivering higher returns needed for the higher operating risk with enclosed mall assets (with its discretionary spending exposure and higher capital intensity)," Woolley said.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$PMZ-UN.TO

Research5h ago

Deutsche Bank Initiates Coverage on DexCom With Buy Rating, $86 Price Target

DexCom (DXCM) has an average rating of Buy and mean price target of $85.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DXCM

Showing 1-20 of 5911